The work by Marcianò et al. consists of the description of only six cases of MRONJ in patients with breast cancer treated with osteoclast inhibitor therapy and CDK4/6 inhibitors among a total of sixteen cases of MRONJ. Here, CDK4 is linked to breast cancer.